Ezetimibe: a novel cholesterol absorption inhibitor (PDF)
Ezetimibe (Zetia), approved in late October, represents the first new class of cholesterol-lowering drugs in 15 years. Ezetimibe, an intestinal cholesterol absorption inhibitor, has a unique mechanism of action, distinct from those of statins and bile acid sequestrants. When used as monotherapy, ezetimibe lowers low-density lipoprotein cholesterol (LDL-C) levels up to 18.5%. Coadministration of ezetimibe with statin therapy reduces LDL-C levels up to an additional 22%. The article reviews ezetimibe?s chemistry, pharmacology, pharmacokinetics, and clinical trial results.
Unifying care management doubled patient outreach with the same staff, and virtual physical therapy is cutting costs, says Populance's Christopher Stanley, M.D.
Christopher Stanley, M.D., MBA, says Henry Ford Health's growth has led Populance to put its push for outside customers on hold and focus on its own system.
Geisinger Health Plan President Jeremy Gaskill says being owned by a health system aligns incentives, cuts payer-provider busywork and speeds care to patients.
Geisinger Health Plan expects Medicaid enrollment to fall roughly 10% as H.R. 1 takes effect, President Jeremy Gaskill says, though the timing is still unclear.
As other insurers pull back, Geisinger Health Plan isn’t exiting any Medicare Advantage plans for 2027 and expects to grow, President Jeremy Gaskill says.
The second part of our interview with Jeremy Gaskill, the president of the Geisinger Health Plan. Gaskill discusses trends in the various segments of the health insurance market—Medicaid, Medicare Advantage, the employer-based commercial market and the ACA marketplace.
In the CONNECT trial, CGM users with type 2 diabetes not on insulin saw larger A1C reductions and more time in range than those using finger-stick testing.